Proxy Results, Management Change/Compensation (Form 8-K)

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

At the Annual Meeting (as defined below) on October 24, 2025, the shareholders of Silo Pharma, Inc. (the "Company") approved an amendment to the Silo Pharma Inc. Amended and Restated 2020 Omnibus Equity Incentive Plan (the "Plan Amendment') to increase the number of shares of common stock reserved for issuance thereunder to 1,400,000 shares from 470,000 shares.

The foregoing descriptions of the Plan Amendment is not complete and are qualified in its entirety by reference to the full text of the Plan Amendment, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated by reference herein.

Item 5.07 Submission of Matters to a Vote of Security Holders.

On October 24, 2025, the Company held its annual meeting of shareholders, (the "Annual Meeting") for the purpose of holding a shareholder vote on the proposals set forth below. A total of 5,142,415 shares of the Company's common stock constituting a quorum, were represented in person or by valid proxies at the Annual Meeting.

At the Annual Meeting, the Company's shareholders (i) re-elected each of Eric Weisblum, Wayne Linsley, Kevin Munoz and Jeff Pavell as members of the Company's board of directors to serve until the next annual meeting of shareholders or until their respective successors have been duly elected and qualified, or until such director's earlier resignation, removal or death; (ii) ratified the appointment of Salberg & Company, P.A. as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025; (iii) approved the grant of discretionary authority to the Company's board of directors (the "Board") to file articles of amendment to the Company's articles of incorporation (the "Articles of Incorporation") to effect a reverse split of the Company's issued common stock at a ratio that is not less than 1-for-2 and not greater than 1-for-20, without reducing the authorized number of shares of the Company's common stock, with the exact ratio to be selected by the Board in its discretion and to be effected, if at all, in the sole discretion of the Board at any time following shareholder approval of the amendment to the our Articles of Incorporation and before October 24, 2026 without further approval or authorization of the Company's shareholders (the "Reverse Stock Split Proposal"); (iv) approved the Plan Amendment; and (v) approved the authorization for the adjournment of the Annual Meeting if necessary or appropriate, including to solicit additional proxies in the event that there are not sufficient votes at the time of the Annual Meeting or adjournment or postponement thereof to approve any of the foregoing proposals (the "Adjournment Proposal").